Key result
In patients with cardiogenic shock, Impella use was associated with 47% short-term mortality and showed no significant difference compared to IABP.
Why the study?
Cardiogenic shock is life-threatening and mechanical circulatory support may impact its clinical course, but the usefulness of the promising Impella device remains debated.
Does the Impella device improve short-term mortality compared to IABP in patients with cardiogenic shock?
Meta-Analysis (n=5,204)
Does the Impella device improve short-term mortality compared to IABP in patients with cardiogenic shock?
In patients with cardiogenic shock, Impella use did not significantly improve short-term mortality compared to IABP but was associated with higher rates of major bleeding and vascular complications.
Answers are grounded in this paper and cite their sources.
No short-term mortality benefit of Impella vs IABP in CS; challenges routine escalation and leaves open need for RCTs.
Introduction: Cardiogenic shock (CS) is a life-threatening condition and mechanical circulatory support (MCS) might exert a relevant impact on its clinical course. Among MCS devices, Impella is very promising. Yet, its usefulness is still debated. We performed a meta-analysis of all studies evaluating the clinical impact of Impella in CS. Methods: All studies including patients with CS and treated with Impella were included. The primary endpoint was short-term mortality. Secondary endpoints were vascular access complications and major bleeding. Data synthesis was obtained using random-effects metanalysis. Results: Thirty-three studies and 5204 patients were included. Short-term mortality was 47%. Meta-regression analysis showed that patients age (p = 0.01), higher support level (p = 0.004) and pre-PCI insertion (p < 0.001) were significant moderators for the primary endpoint. Vascular access complications were registered in 6.4% of cases, whereas age (p = 0.05) and diabetes (p = 0.007) were significant predictors. Major bleeding occurred in 16.4% of patients. Meta-analysis of the subgroup of studies comparing Impella to IABP showed no significant difference in short-term mortality (RR = 1.08, p = 0.45), while rates of vascular access complications (p < 0.001) or major bleeding (p < 0.001) were significantly higher with Impella. Subgroup and metaregression analyses showed that these results were influenced by lower adoption rates of higher degree of MCS support (p = 0.003), and by higher vascular complications rates (p = 0.014). Conclusions: Our results suggest that the choice of adequate device size, careful patients selection and optimal timing of MCS initiation are key to clinical success with Impella in CS. Large prospective studies are mandatory to confirm these results deriving from retrospective studies.
No takes yet. Share an insight, caveat, or question.
Panuccio et al. (2022) conducted a meta-analysis in Cardiogenic shock (n=5,204). Impella vs. IABP was evaluated on short-term mortality (RR 1.08, p=0.45). In patients with cardiogenic shock, Impella use was associated with 47% short-term mortality and showed no significant difference compared to IABP.
Synapse has enriched 10 related papers. Consider them for comparative context: